JyotiMalhotraMD

Oncology • Irvine, CA

Thoracic Cancer

Physician

Join to view full profile

Dr. Malhotra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Malhotra's full profile

Already have an account?

Office
1000 FivePoint
Irvine, CA 92618
Phone+1 949-671-4673

Education & Training

MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 2005

Certifications & Licensure

CA State Medical License 2022 - 2026
NY State Medical License 2010 - 2026
NJ State Medical License 2015 - 2023
DC State Medical License 2006 - 2009
PA State Medical License 2009 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Start of enrollment: 2011 Nov 23
Active, not recruiting
Phase 1
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors Start of enrollment: 2017 May 04
Terminated
Phase 1, Phase 2
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
Active, not recruiting
Phase 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones Start of enrollment: 2020 Aug 04
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review.
Jyoti Malhotra, Isa Mambetsariev, Gregory Gilmore, Jeremy Fricke, Arin Nam
JAMA Oncology. 2025-01-01
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advance...
Jyoti Malhotra, Ramya Muddasani, Jeremy Fricke, Isa Mambetsariev, Amanda Reyes
JCO Precision Oncology. 2024-12-01

Lectures

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 24th, 2021
How Covid Vaccine Diplomacy Is Helping India Win Back Its NeighbourhoodJanuary 15th, 2021
Join now to see all